Zymeworks Inc (OQ:ZYME)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 108 Patriot Drive, Suite A
Tel: N/A
Website: https://www.zymeworks.com
IR: See website
Key People
Kenneth H. Galbraith
Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer
Paul A. Moore
Chief Scientific Officer
Business Overview
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.
Financial Overview
For the three months ended 31 March 2024, Zymeworks Inc revenues decreased 72% to $10M. Net loss increased 30% to $31.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects discovery, development and commercialization segment loss increase of 39% to $37.8M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.36 to -$0.42.
Employees: 275 as of Mar 31, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $289.97M as of Mar 31, 2024
Annual revenue (TTM): $50.46M as of Mar 31, 2024
EBITDA (TTM): -$138.91M as of Mar 31, 2024
Net annual income (TTM): -$125.97M as of Mar 31, 2024
Free cash flow (TTM): -$77.13M as of Mar 31, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 71,275,527 as of Apr 30, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.